• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Comera Life Sciences Shares Jumped 101%; Here Are 74 Biggest Movers From Yesterday

    9/14/22 3:58:11 AM ET
    $AAPL
    $ADTX
    $AEHR
    $AKRO
    Computer Manufacturing
    Technology
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AAPL alert in real time by email

    Gainers

    • Akero Therapeutics, Inc. (NASDAQ:AKRO) shares jumped 136.8% to settle at $29.05 on Tuesday after the company's Phase 2b HARMONY study met its primary endpoint for both the 50mg and 28mg EFX dose groups.
    • Aditxt, Inc. (NASDAQ:ADTX) jumped 113.8% to close at $0.37.
    • Comera Life Sciences Holdings, Inc. (NASDAQ:CMRA) surged 101% to close at $3.86 after a late Monday Form 4 filing showed multiple insider purchases of the stock.
    • NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO) climbed 79.3% to close at $29.90 on Tuesday as the stock started trading on a 1-for-30 reverse split basis.
    • 89bio, Inc. (NASDAQ:ETNB) shares rose 40% to close at $7.00. Analysts reportedly said Akero's NASH data could be a positive for the company's Pegoza program in NASH.
    • Motorsport Games Inc. (NASDAQ:MSGM) climbed 28.1% to close at $0.97. Motorsport Games, last month, reported worse-than-expected Q2 EPS results.
    • Akouos, Inc. (NASDAQ:AKUS) gained 28% to close at $4.48. The FDA has signed off Akouos Investigational New Drug application to initiate a Phase 1/2 trial of AK-OTOF, gene therapy for otoferlin gene (OTOF)-mediated hearing loss.
    • Infobird Co., Ltd (NASDAQ:IFBD) jumped 28% to settle at $2.47.
    • Golden Path Acquisition Corporation (NASDAQ:GPCO) rose 22.4% to settle at $8.69.
    • Ensysce Biosciences, Inc. (NASDAQ:ENSC) gained 22.3% to close at $0.4131.
    • Immuneering Corporation (NASDAQ:IMRX) jumped 22.1% to close at $12.00. Immuneering recently submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for its product candidate IMM-1-104 in development for the treatment of advanced RAS mutant solid tumors.
    • Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) rose 21% to close at $0.2299.
    • VNET Group, Inc. (NASDAQ:VNET) gained 20.7% to close at $5.66 after the company announced the receipt of a preliminary non-binding proposal to acquire all of its shares and formation of a special committee to review the proposal.
    • Cosmos Holdings Inc. (NASDAQ:COSM) climbed 19.7% to settle at $0.4216. Cosmos Health’s subsidiary SkyPharm recently launched its first Sky Premium Life products on Amazon in the U.S.
    • Palisade Bio, Inc. (NASDAQ:PALI) jumped 18.3% to settle at $0.1782. Palisade Bio was Granted U.S. patent titled 'Administration of serine protease inhibitors to the stomach.'
    • Aprea Therapeutics, Inc. (NASDAQ:APRE) gained 17.7% to close at $0.9299.
    • Phunware, Inc. (NASDAQ:PHUN) surged 15.6% to settle at $1.63.
    • NLS Pharmaceutics AG (NASDAQ:NLSP) gained 14.2% to close at $1.12. Laidlaw & Co. recently initiated coverage on NLS Pharmaceutics with a Buy rating and announced a price target of $6.
    • iBio, Inc. (NYSE:IBIO) rose 13.7% to close at $0.3080 after declining over 4% on Monday.
    • Planet Labs PBC (NYSE:PL) gained 13.5% to close at $6.15 after the company reported better-than-expected Q2 results and raised guidance.
    • Aehr Test Systems (NASDAQ:AEHR) gained 13.5% to close at $15.99 after the company received a wafer level burn-in system order.
    • HilleVax, Inc. (NASDAQ:HLVX) rose 12.4% to close at $22.01.
    • Hycroft Mining Holding Corporation (NASDAQ:HYMC) rose 12.1% to close at $0.8914. The company earlier reported initial drill results from its 2022-2023 exploration program.
    • Entrada Therapeutics, Inc. (NASDAQ:TRDA) surged 10.3% to settle at $13.14.
    • Tyme Technologies, Inc. (NASDAQ:TYME) gained 9.1% to close at $0.2807 after gaining around 4% on Monday.
    • V2X, Inc. (NYSE:VVX) gained 8.6% to close at $41.25.
    • LSB Industries, Inc. (NYSE:LXU) gained 6.3% to close at $17.04. Piper Sandler initiated coverage on LSB Industries with an Overweight rating and announced a price target of $26.
    • Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) shares rose 4.9% to close at $0.7659 after the FDA granted Syros Pharmaceuticals Orphan Drug Designation for the treatment of pancreatic cancer.
    • Core & Main, Inc. (NYSE:CNM) rose 2.5% to close at $25.11 following upbeat Q2 results.


    Losers

    • Cardiff Oncology, Inc. (NASDAQ:CRDF) shares dipped 41.1% to close at $1.89 on Tuesday. Following a strategic review, Cardiff Oncology decided it will not independently fund any future clinical activities in metastatic castrate-resistant prostate cancer (mCRPC), citing clinical data and therapeutic landscape.
    • Rent the Runway, Inc. (NASDAQ:RENT) shares dropped 38.7% to close at $3.02 after the company reported issued Q3 guidance below estimates and announced a workforce reduction of 24% of corporate employees. Credit Suisse downgraded the stock from Outperform to Neutral and lowered the price target from $7 to $4.
    • InMed Pharmaceuticals Inc. (NASDAQ:INM) fell 35.7% to close at $12.07. InMed Pharmaceuticals recently announced a $6 million private placement priced at $8.68 per share.
    • Codiak BioSciences, Inc. (NASDAQ:CDAK) dipped 33.5% to close at $1.11 after the company priced 13.33 million share offering plus accompanying warrants at combined price of $1.50 per share plus warrant.
    • Benitec Biopharma Inc. (NASDAQ:BNTC) declined 28.3% to close at $0.4550 as the company reported pricing of $18 million underwritten public offering.
    • Edgewise Therapeutics, Inc. (NASDAQ:EWTX) dropped 24% to settle at $10.32. Edgewise Therapeutics announced a proposed $100 million offering of common stock.
    • Nocera, Inc. (NASDAQ:NCRA) fell 22.5% to close at $1.96.
    • Venus Concept Inc. (NASDAQ:VERO) dropped 21.5% to close at $0.5508.
    • AMTD Digital Inc. (NYSE:HKD) declined 21.1% to close at $46.00.
    • Braze, Inc. (NASDAQ:BRZE) fell 19.3% to close at $35.18 after the company reported Q2 earnings results and issued Q3 2023 adjusted EPS guidance below estimates.
    • PolyPid Ltd. (NASDAQ:PYPD) fell 18.7% to settle at $1.39 after jumping 58% on Monday. The company earlier announced it will present Phase 2 D-PLEX₁₀₀ data at the European Society for Coloproctology Scientific Conference next week.
    • Ventoux CCM Acquisition Corp. (NASDAQ:VTAQ) dropped 17.8% to close at $7.11.
    • Relay Therapeutics, Inc. (NASDAQ:RLAY) shares fell 16.6% to close at $24.03. Relay Therapeutics priced 11.32 million share public offering of common stock at $26.50 per share.
    • Soluna Holdings, Inc. (NASDAQ:SLNH) fell 15.6% to close at $2.66.
    • Hut 8 Mining Corp. (NASDAQ:HUT) dipped 15.4% to settle at $2.03.
    • Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) dropped 15.2% to close at $26.45.
    • Jasper Therapeutics, Inc. (NASDAQ:JSPR) fell 15.1% to settle at $1.58.
    • Boxed, Inc. (NYSE:BOXD) declined 14.8% to settle at $0.9283.
    • Kingsoft Cloud Holdings Limited (NASDAQ:KC) fell 14.4% to close at $2.26.
    • Innovid Corp. (NYSE:CTV) fell 14.2% to close at $3.08. Morgan Stanley initiated coverage on Innovid with an Underweight rating and announced a price target of $2.7.
    • The RealReal, Inc. (NASDAQ:REAL) declined 14.1% to close at $2.26.
    • Magic Empire Global Limited (NASDAQ:MEGL) dropped 14% to close at $5.16.
    • Syneos Health, Inc. (NASDAQ:SYNH) fell 13.7% to settle at $54.72.
    • LumiraDx Limited (NASDAQ:LMDX) declined 13.6% to settle at $1.33.
    • Rubius Therapeutics, Inc. (NASDAQ:RUBY) fell 13.4% to close at $0.9270 after the company discontinued ongoing Phase 1 trials of RTX-240 and RTX-224 in advanced solid tumors.
    • The Children's Place, Inc. (NASDAQ:PLCE) declined 13.4% to settle at $35.17.
    • Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) slipped 13.4% to close at $13.91.
    • Unity Software Inc. (NYSE:U) dropped 13.4% to close at $36.66 after Applovin announced it does not intend to submit another proposal to combine with the company and has withdrawn its Aug. 9 proposal.
    • Carvana Co. (NYSE:CVNA) fell 12.9% to close at $36.81.
    • MicroStrategy Incorporated (NASDAQ:MSTR) dropped 12.1% to close at $231.25 after August CPI data showed greater-than-expected US inflation.
    • WalkMe Ltd. (NASDAQ:WKME) declined 11.9% to close at $9.74. WalkMe announced the departure of Chief Financial Officer Andrew Casey.
    • Pacific Biosciences of California, Inc. (NASDAQ:PACB) dipped 11.7% to close at $6.14.
    • Asana, Inc. (NYSE:ASAN) fell 11.5% to close at $25.42.
    • Wayfair Inc. (NYSE:W) fell 11.1% to close at $49.76.
    • Upstart Holdings, Inc. (NASDAQ:UPST) fell 10.9% to close at $24.97.
    • Peloton Interactive, Inc. (NASDAQ:PTON) fell 10.3% to close at $9.91 after the company announced Executive Chair John Foley will step down, effective Sept. 12. Karen Boone has been elected Chairperson of the Board.
    • BridgeBio Pharma, Inc. (NASDAQ:BBIO) fell 10.1% to close at $11.11.
    • Crocs, Inc. (NASDAQ:CROX) dropped 9.8% to settle at $75.39 amid overall market weakness as August CPI readings showed inflation came in greater than expected.
    • NVIDIA Corporation (NASDAQ:NVDA) tumbled 9.5% to close at $131.31. Shares of semiconductor stocks at large traded lower after August CPI data showed greater-than-expected US inflation, which has caused economic concerns and raised expectations for aggressive Fed policy. Fed rate hikes could drive a slowdown in the economy, which could pressure demand in semiconductor and chip end markets.
    • Tuesday Morning Corporation (NASDAQ:TUEM) fell 8.8% to close at $0.1766. The company recently announced it has entered into an agreement to secure $32 million in convertible debt financing.
    • Coinbase Global, Inc. (NASDAQ:COIN) declined 8.8% to settle at $75.25 as cryptocurrencies fell following worse-than-expected US inflation data.
    • Amazon.com, Inc. (NASDAQ:AMZN) dipped 7.1% to close at $126.82 after August CPI data showed greater-than-expected US inflation.
    • AppLovin Corporation (NASDAQ:APP) fell 6.4% to close at $26.68. Applovin announced it does not intend to submit another proposal to combine with Unity Software and has withdrawn its Aug. 9 proposal.
    • Apple Inc. (NASDAQ:AAPL) fell 5.9% to close at $153.84 amid overall market weakness after August CPI readings showed inflation came in greater than expected.
    • Microsoft Corporation (NASDAQ:MSFT) fell 5.5% to settle at $251.99 after August CPI data showed greater-than-expected US inflation.
    Get the next $AAPL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AAPL
    $ADTX
    $AEHR
    $AKRO

    CompanyDatePrice TargetRatingAnalyst
    Coinbase Global Inc.
    $COIN
    2/12/2026$120.00Buy → Neutral
    Monness Crespi & Hardt
    Entrada Therapeutics Inc.
    $TRDA
    2/11/2026$20.00Buy
    Guggenheim
    Kingsoft Cloud Holdings Limited
    $KC
    2/11/2026$15.60Neutral → Buy
    Goldman
    Apple Inc.
    $AAPL
    2/10/2026$325.00 → $340.00Outperform
    Bernstein
    Peloton Interactive Inc.
    $PTON
    2/10/2026Buy → Hold
    Argus
    Unity Software Inc.
    $U
    2/10/2026$38.00Perform → Outperform
    Oppenheimer
    Microsoft Corporation
    $MSFT
    2/9/2026Buy → Hold
    Melius
    Amazon.com Inc.
    $AMZN
    2/6/2026$300.00 → $280.00Buy
    Monness Crespi & Hardt
    More analyst ratings

    $AAPL
    $ADTX
    $AEHR
    $AKRO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Siokas Grigorios bought $120,000 worth of shares (291,262 units at $0.41), increasing direct ownership by 4% to 8,473,382 units (SEC Form 4)

    4 - Cosmos Health Inc. (0001474167) (Issuer)

    2/12/26 2:20:08 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    Director Smith Gary B bought $313 worth of shares (20 units at $15.66) and sold $254 worth of shares (20 units at $12.69) (SEC Form 4)

    4 - Planet Labs PBC (0001836833) (Issuer)

    2/3/26 6:35:28 PM ET
    $PL
    Radio And Television Broadcasting And Communications Equipment
    Technology

    President/CEO Gilad Oren bought $25,009 worth of shares (28,100 units at $0.89), increasing direct ownership by 8% to 373,720 units (SEC Form 4)

    4 - Aprea Therapeutics, Inc. (0001781983) (Issuer)

    2/2/26 4:08:08 PM ET
    $APRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AAPL
    $ADTX
    $AEHR
    $AKRO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Coinbase Global downgraded by Monness Crespi & Hardt with a new price target

    Monness Crespi & Hardt downgraded Coinbase Global from Buy to Neutral and set a new price target of $120.00

    2/12/26 7:44:13 AM ET
    $COIN
    Finance: Consumer Services
    Finance

    Guggenheim initiated coverage on Entrada Therapeutics with a new price target

    Guggenheim initiated coverage of Entrada Therapeutics with a rating of Buy and set a new price target of $20.00

    2/11/26 7:51:55 AM ET
    $TRDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kingsoft Cloud upgraded by Goldman with a new price target

    Goldman upgraded Kingsoft Cloud from Neutral to Buy and set a new price target of $15.60

    2/11/26 7:42:03 AM ET
    $KC
    Computer Software: Prepackaged Software
    Technology

    $AAPL
    $ADTX
    $AEHR
    $AKRO
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    March 11, 2025 - FDA Roundup: March 11, 2025

    For Immediate Release: March 11, 2025 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:Today, the FDA published a General Correspondence Letter issued to Mid-Link Technology Testing Co., Ltd. The FDA is vigilant in ensuring data submitted to the FDA can be relied upon to assess the effectiveness, safety, or risk of a device. The FDA has noted an incr

    3/13/25 3:14:00 PM ET
    $AMZN
    Catalog/Specialty Distribution
    Consumer Discretionary

    FDA Approval for ATTRUBY issued to BRIDGEBIO PHARMA INC

    Submission status for BRIDGEBIO PHARMA INC's drug ATTRUBY (ORIG-1) with active ingredient ACORAMIDIS has changed to 'Approval' on 11/22/2024. Application Category: NDA, Application Number: 216540, Application Classification: Type 1 - New Molecular Entity

    11/25/24 8:41:11 AM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    September 17, 2024 - FDA Roundup: September 17, 2024

    For Immediate Release: September 17, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA issued a draft guidance, “Integrating Randomized Controlled Trials for Drug and Biological Products into Routine Clinical Practice,” which, when finalized, will support the conduct of randomized controlled trials with streamlined protocols a

    9/17/24 2:34:22 PM ET
    $AAPL
    Computer Manufacturing
    Technology

    $AAPL
    $ADTX
    $AEHR
    $AKRO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Sunbit Appoints Shachar G. Scott as Chief Marketing Officer to Accelerate its Next Phase of Growth

    Veteran global marketing leader joins from Meta as Sunbit scales products, partnerships and infrastructure to serve millions more consumers Sunbit, the personalized financial partner for everyday life, today announced the appointment of Shachar G. Scott as Chief Marketing Officer, signaling a pivotal next chapter in the company's growth. Scott brings more than 25 years of experience building and scaling global brands across technology and consumer products with leadership roles at Meta (NASDAQ:META), Apple (NASDAQ:AAPL), Bumble (NASDAQ:BMBL) and Snap (NYSE:SNAP). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260212757677/en/S

    2/12/26 10:14:00 AM ET
    $AAPL
    $BMBL
    $META
    Computer Manufacturing
    Technology
    Computer Software: Programming Data Processing

    Aprea Therapeutics Strengthens Global Patent Portfolio in DNA Damage Response (DDR) Cancer Therapeutics, Paving Way for Pipeline Growth

    New patents granted in 2025 in Australia and Japan bolster global IP coverage for Aprea's WEE1 and ATR programs. Core patent families are expected to provide exclusivity into 2045. Lead WEE1 inhibitor candidate APR-1051 is advancing in Phase 1 trials, with early clinical proof of concept demonstrated and multiple 2026 data readouts anticipated Broad intellectual property protection and ongoing clinical progress position Aprea for long-term value creation DOYLESTOWN, Pa., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea" or the "Company"), a clinical-stage biopharmaceutical company developing innovative therapies that exploit cancer-specific vulnerabilitie

    2/12/26 8:30:00 AM ET
    $APRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Benitec Biopharma Releases Second Quarter 2026 Financial Results and Provides Operational Update

    -The first 4 Patients enrolled into Cohort 1 of the BB-301 Phase 1b/2a treatment study have completed the 12-month statistical follow-up period, and all 4 Completers were formal Responders to BB-301 at the 12-month follow-up timepoint demonstrating durable response to BB-301- -Patient 1 of Cohort 1 completed the 24-month follow-up timepoint, and at the 24-month post-treatment timepoint Patient 1 continued to experience the disease-modifying effects of BB-301, with deepening improvements in post-swallow residue and total dysphagic symptom burden as compared to the 12-month follow-up timepoint- - An update on the Interim clinical results for Cohort 2 is planned for mid-2026- -FDA meeting to

    2/12/26 8:30:00 AM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AAPL
    $ADTX
    $AEHR
    $AKRO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $AAPL
    $ADTX
    $AEHR
    $AKRO
    SEC Filings

    View All

    Chief Executive Officer Siokas Grigorios bought $120,000 worth of shares (291,262 units at $0.41), increasing direct ownership by 4% to 8,473,382 units (SEC Form 4)

    4 - Cosmos Health Inc. (0001474167) (Issuer)

    2/12/26 2:20:08 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    President, Special Projects Taira Thomas sold $417,271 worth of shares (1,047 units at $398.54), decreasing direct ownership by 2% to 66,625 units (SEC Form 4)

    4 - CARVANA CO. (0001690820) (Issuer)

    2/11/26 6:42:12 PM ET
    $CVNA
    Retail-Auto Dealers and Gas Stations
    Consumer Discretionary

    SEC Form 4 filed by Chief Medical Officer Jones Mitchell Lawrence

    4 - PALISADE BIO, INC. (0001357459) (Issuer)

    2/11/26 5:34:45 PM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-K filed by Crocs Inc.

    10-K - Crocs, Inc. (0001334036) (Filer)

    2/12/26 3:03:37 PM ET
    $CROX
    Shoe Manufacturing
    Consumer Discretionary

    SEC Form SCHEDULE 13G filed by Wayfair Inc.

    SCHEDULE 13G - Wayfair Inc. (0001616707) (Subject)

    2/12/26 2:15:20 PM ET
    $W
    Catalog/Specialty Distribution
    Consumer Discretionary

    SEC Form SCHEDULE 13G filed by Jasper Therapeutics Inc.

    SCHEDULE 13G - Jasper Therapeutics, Inc. (0001788028) (Subject)

    2/12/26 10:33:02 AM ET
    $JSPR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AAPL
    $ADTX
    $AEHR
    $AKRO
    Leadership Updates

    Live Leadership Updates

    View All

    Sunbit Appoints Shachar G. Scott as Chief Marketing Officer to Accelerate its Next Phase of Growth

    Veteran global marketing leader joins from Meta as Sunbit scales products, partnerships and infrastructure to serve millions more consumers Sunbit, the personalized financial partner for everyday life, today announced the appointment of Shachar G. Scott as Chief Marketing Officer, signaling a pivotal next chapter in the company's growth. Scott brings more than 25 years of experience building and scaling global brands across technology and consumer products with leadership roles at Meta (NASDAQ:META), Apple (NASDAQ:AAPL), Bumble (NASDAQ:BMBL) and Snap (NYSE:SNAP). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260212757677/en/S

    2/12/26 10:14:00 AM ET
    $AAPL
    $BMBL
    $META
    Computer Manufacturing
    Technology
    Computer Software: Programming Data Processing

    Circana Appoints Highly Regarded Business Leaders to Board of Directors

    Chicago, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Circana LLC, a leading global provider of data, insights, and advisory services, today announced the appointment of three new members to its Board of Directors: Brian Cornell, Executive Chair of Target Corp.; Lauren Cooks Levitan, Co-Founder and Co-CEO of ROOT and Lead Independent Director at e.l.f. Beauty, Inc.; and Rohit Prasad, former Senior Vice President and Head Scientist of Artificial General Intelligence at Amazon.com, Inc. "These appointments strengthen the Board's ability to guide Circana's strategy and accelerate the value we deliver to our global clients," said Stuart Aitken, President and CEO of Circana. "We are focused on advancing

    2/11/26 8:00:00 AM ET
    $AMZN
    $TGT
    Catalog/Specialty Distribution
    Consumer Discretionary
    Department/Specialty Retail Stores

    Unity Appoints Bernard Kim to its Board of Directors and Announces Board Transitions

    Unity (NYSE:U), the world's leading game engine, today announced the appointment of gaming and technology veteran Bernard Kim as an independent director to its Board of Directors, effective May 1, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260210709281/en/Bernard Kim "Bernard brings deep experience building and scaling global, public companies at the intersection of games and technology," said Jim Whitehurst, Chairman of Unity's Board of Directors. "His leadership across mobile gaming, advertising technology, and consumer platforms will be a valuable addition to the Unity Board." "Unity plays a foundational role in h

    2/10/26 4:15:00 PM ET
    $U
    Computer Software: Prepackaged Software
    Technology

    $AAPL
    $ADTX
    $AEHR
    $AKRO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Rocket Pharmaceuticals Inc.

    SC 13D/A - ROCKET PHARMACEUTICALS, INC. (0001281895) (Subject)

    12/16/24 7:51:51 PM ET
    $RCKT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Carvana Co.

    SC 13D/A - CARVANA CO. (0001690820) (Subject)

    12/16/24 6:13:26 PM ET
    $CVNA
    Retail-Auto Dealers and Gas Stations
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by PolyPid Ltd.

    SC 13G/A - PolyPid Ltd. (0001611842) (Subject)

    12/12/24 7:05:07 AM ET
    $PYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AAPL
    $ADTX
    $AEHR
    $AKRO
    Financials

    Live finance-specific insights

    View All

    BridgeBio Reports Positive Phase 3 Topline Results for Oral Infigratinib with the First Statistically Significant Improvements in Body Proportionality in Achondroplasia

    - PROPEL 3 successfully met the primary endpoint of change from baseline in AHV at Week 52 (p<0.0001) - Change from baseline in AHV was superior to placebo at Week 52 with a mean treatment difference against placebo of +2.10 cm/year; the LS mean was +1.74 cm/year - In a pre-specified exploratory analysis of the key secondary endpoint, oral infigratinib achieved the first statistically significant improvement in body proportionality against placebo in achondroplasia, demonstrating an LS mean treatment difference of -0.05 (p<0.05) against placebo in children younger than 8 years old (>50% of the participants) - PROPEL 3 successfully met the key secondary endpoint of change from baseline in

    2/12/26 7:30:00 AM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Crocs, Inc. Reports Fourth Quarter and Full-Year 2025 Results; Issues First Quarter and Full-Year 2026 Outlook

    Full-Year 2025 Results Outperform Expectations on Revenue and Earnings Per ShareStrong Cash Flow Enabled Repurchase of 6.5 Million Shares for $577 Million in 2025Expects to Deliver Earnings Per Share Growth in Full-Year 2026BROOMFIELD, Colo., Feb. 12, 2026 /PRNewswire/ -- Crocs, Inc. (NASDAQ:CROX), a world leader in innovative casual footwear for all, today announced its fourth quarter and full-year 2025 financial results. "We ended 2025 on a strong note with a better-than-expected Holiday quarter. For the year, revenue exceeded $4 billion, led by low-double digit international growth for the Crocs Brand. At the same time, we accelerated our strategic actions to strengthen the long-term heal

    2/12/26 7:00:00 AM ET
    $CROX
    Shoe Manufacturing
    Consumer Discretionary

    AppLovin Announces Fourth Quarter and Full Year 2025 Financial Results

    AppLovin Corporation (NASDAQ:APP) ("AppLovin"), a leading marketing platform, today announced financial results for the quarter and full year ended December 31, 2025 and posted a financial update on its Investor Relations website located at https://investors.applovin.com. Fourth Quarter and Full Year 2025 Financial Highlights:   Quarter Ended       Year Ended       December 31,       December 31,     (In millions, except percentages)   2025     2024   % Change     2025     2024   % Change R

    2/11/26 4:05:00 PM ET
    $APP
    Computer Software: Programming Data Processing
    Technology